Wang N P, Bacchi C E, Jiang J J, McNutt M A, Gown A M
Department of Pathology, University of Washington, Seattle 98195, USA.
Mod Pathol. 1996 May;9(5):496-506.
There has been persistent controversy regarding the nature of cell differentiation in alveolar soft-part sarcoma (ASPS) since its first description in 1952. Some studies suggest that ASPS might represent an unusual variant of skeletal muscle tumor. Given the availability of new monoclonal antibodies to probe for skeletal muscle differentiation and the rapid advance in immunocytochemical techniques for deparaffinized, formalin-fixed tissue sections, we wished to test the proposed hypothesis that ASPS might represent a new type of rhabdomyosarcoma. Twelve archival samples of ASPS were retrieved, and we investigated the expression of two myogenic regulatory proteins, MyoD1 and myogenin, as well as other muscle-associated proteins, using sensitive immunocytochemical techniques. Despite the presence of desmin immunostaining in six ASPSs, no tumors were positive for either muscle actin or myoglobin. Most importantly, no specimen showed nuclear expression of MyoD1 or myogenin. In 11 tumors, however, there was considerable granular immunostaining in the tumor cell cytoplasm with the anti-MyoD1 monoclonal antibody 5.8A, a phenomenon observed in various nonmuscle normal and neoplastic tissues with this antibody. To analyze the exact nature of immunostaining of MyoD1 and desmin in ASPS, biochemical analyses using available fresh frozen tumor tissue were performed. Although a 53-kDa band was noted with antidesmin antibody on Western blot analysis, no specific protein band that corresponds to the 45-kDa MyoD1 was detected with antibody 5.8A. These results confirm the presence of desmin in ASPS but argue against authentic expression of MyoD1. They also suggest that the cytoplasmic immunostaining observed with anti-MyoD1 antibody 5.8A most likely represents a nonspecific cross-reaction with an unknown cytoplasmic antigen. Considering the master role that MyoD1 and myogenin play in skeletal muscle commitment and differentiation and the lack of expression of these two proteins in ASPS as determined immunocytochemically and biochemically, we think that the histogenesis of ASPS remains unknown.
自1952年首次描述肺泡软组织肉瘤(ASPS)以来,关于其细胞分化的性质一直存在争议。一些研究表明,ASPS可能代表骨骼肌肿瘤的一种不寻常变体。鉴于有新的单克隆抗体可用于检测骨骼肌分化,且针对脱蜡、福尔马林固定组织切片的免疫细胞化学技术迅速发展,我们希望检验ASPS可能代表一种新型横纹肌肉瘤这一假说。我们检索了12份ASPS存档样本,并用灵敏的免疫细胞化学技术研究了两种生肌调节蛋白MyoD1和肌细胞生成素以及其他肌肉相关蛋白的表达。尽管6例ASPS中有结蛋白免疫染色,但没有肿瘤对肌动蛋白或肌红蛋白呈阳性反应。最重要的是,没有标本显示MyoD1或肌细胞生成素的核表达。然而,在11例肿瘤中,用抗MyoD1单克隆抗体5.8A检测到肿瘤细胞质中有大量颗粒状免疫染色,该抗体在各种非肌肉正常组织和肿瘤组织中都有此现象。为分析ASPS中MyoD1和结蛋白免疫染色的确切性质,我们用现有的新鲜冷冻肿瘤组织进行了生化分析。虽然在蛋白质印迹分析中用抗结蛋白抗体检测到一条53 kDa的条带,但用抗体5.8A未检测到与45 kDa MyoD1相对应的特异性蛋白条带。这些结果证实了ASPS中存在结蛋白,但反对MyoD1的真实表达。它们还表明,用抗MyoD1抗体5.8A观察到的细胞质免疫染色很可能代表与一种未知细胞质抗原的非特异性交叉反应。考虑到MyoD1和肌细胞生成素在骨骼肌定向分化中的主导作用以及免疫细胞化学和生化检测确定这两种蛋白在ASPS中缺乏表达,我们认为ASPS的组织发生仍然不明。